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Gallium-68: Radiolabeling of 
Radiopharmaceuticals for PET 
Imaging - A Lot to Consider
Michael Meisenheimer, Yury Saenko and Elisabeth Eppard
Abstract
Gallium-68 was applied for positron emission tomography (PET) imaging 
already in the early beginnings of PET imaging. Today, with the introduction of 
PSMA-targeting tracers (e.g. PSMA-11, PSMA-617, and PSMA-I&T), the number of 
clinical applications of 68Ga-radiopharmaceuticals for diagnostic imaging has grown 
considerably. This development was initiated and supported already in the mid-
2000s by the commercial availability of 68Ge/68Ga generators designed for clinical 
usage. This progression was accompanied by the development of several purifica-
tion methods to generator eluate as well as sophisticated 68Ga-radiopharmaceuticals. 
Due to the 68Ga-rush, the need for implementation of gallium-68 (depending on 
production route) and its certain tracers into the pharmacopeia increased. Based on 
the specifications given by the pharmacopeia, interest focused on the development 
of automated synthesis systems, 99mTc-analog kits with regard to patient as well as 
operator safety.
Keywords: gallium-68, radiopharmaceuticals, production, quality control,  
clinical use
1. Introduction
In recent years, 68Ga-radiopharmaceuticals gained more and more attention 
due to their steadily growing clinical application. Facilitated is this development 
by increasing interest in the application of its “theranostic twin” lutetium-177. 
Combining both, gallium-68 and lutetium-177, enables diagnostic molecular imag-
ing followed by personalized treatment based on the diagnostic scan [1].
This concept is well established for treatment of neuroendocrine tumors (NETs) 
using peptide receptor radionuclide therapy (PRRT). This approach allows the 
targeted treatment of inoperable or metastatic NETs already proven in multiple 
clinical trials employing radiolabeled somatostatin analogs [2–9]. Based on the 
data received, the U.S. Food and Drug Administration (FDA) recently approved 
177Lu-labeled DOTA-TATE for PRRT treatment. However, not only for NETs, but 
also for other types of cancer (e.g. prostate cancer (PC)), lutetium-177 is of interest, 
reflected in numerous clinical trials registered at https://clinicaltrials.gov (keyword: 
lutetium-177; 87 trials; 12/9/2019). Even more trials are enrolled for its diagnostic 
counterpart gallium-68 (keyword: gallium-68; 268 trials; 12/9/2019). While 
only a handful clinical trials were conducted before 2012 for both radionuclides 
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(gallium-68, 12 trials between 1991 and 2011; lutetium-177, 16 trials between 1996 
and 2011) both have increasingly found application in clinical routine reflected in 
the rapidly increasing amount of enrolled phase 1–3 studies.
Although, gallium-68 was already proposed for medical use by Gleason [10] 
its way to clinical application was not possible without the advancement of the 
primary generator design. Providing [68Ga]GaCl3 and containing only trace levels 
of the long-living mother radionuclide germanium-68 regarding 68Ga-activity, the 
commercially availability of generator simplified research and motivated develop-
ments with a view to a broad routine application. The launch of this new type of 
68Ga-generator together with decades of research in chelation chemistry and drug 
discovery resulted in the design of 68Ga-radiopharmaceuticals of high affinity/selec-
tivity for their biological targets [11–13].
The advantages of the generator availability and the easy one-step che-
lation chemistry ensured the relatively fast and broad application of the 
68Ga-radiopharmaceuticals even in smaller institutions. However, exactly these 
advantages lead to problems in the supply today and require new developments in 
order to meet the growing demands.
2. Application: why choosing a radiometal?
What is the advantage of radiometals for an application in nuclear medicine? 
With carbon-11 and mostly fluor-18, two radionuclides for positron emission 
tomography (PET) are available, which can be used for radiolabeling without 
appreciably altering the biological properties of the compounds in addition to their 
favorable decay characteristics. However, the disadvantage of radiometals, the need 
for a chelator is also their advantage over fluor-18 and carbon-11.
Due to this, radiolabeling with radiometals is very easy, can be conducted 
in aqueous solution and with the right choice of chelator possible under mild 
conditions. That enables radiolabeling of temperature or organic solvent sensi-
tive compounds (e.g. antibodies). Additionally, the choice of chelator provides 
the possibility of radiolabeling one compound with different radiometals. Thus, 
Figure 1. 
Depiction of the theranostic concept: utilizing one compound for a variety of applications in patient-centered 
care radiolabeled with different radionuclide.
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widespread application (PET, single photon emission computed tomography 
(SPECT), magnet resonance tomography (MRT) and therapy) of the compound 
only by exchange of the radiometal with minimum changes in biological behavior 
is possible. This facilitates patient-centered care from diagnosis via molecular 
imaging, over treatment planning, prognosis and monitoring utilizing one com-
pound (Figure 1).
Advantages in favor of gallium-68 compared with other appropriate radiometals 
are its favorable decay characteristics, its (commercial) availability and the possible 
combination with lutetium-177 as theranostic pair (Figure 2). Also gallium-68 possi-
bly provides patient care in places where cyclotron-produced fluor-18 is not obtainable.
3. Current applications of 68Ga-radiopharmaceuticals
Currently gallium-68 is most widely used in the diagnosis of prostate cancer in 
the form of [68Ga]Ga-PSMA-11, respectively. [68Ga]Ga-PSMA-617 together with 
[177Lu]Lu-DOTA-PSMA-617 forms a theranostic couple, which is very well suited 
for the diagnosis or treatment of prostate cancer as the 68Ga/177Lu-radiolabelled 
tracers show a very similar biological behavior. Due to similarities in chemical 
behavior, identical (in case of PSMA-617) precursors can be radiolabelled using the 
same or similar equipment, synthesis and quality control methods [14].
The second, but longest known and best evaluated, 68Ga theranostic pair is used 
for neuroendocrine tumors in combination with various somatostatin analogs. 
The three most widely used analogs of somatostatin with gallium-68 are [68Ga]
Ga-DOTA-TOC, [68Ga]Ga-DOTA-TATE, [68Ga]Ga-DOTA-LAN or [68Ga]Ga-DOTA-
NOC [15]. As a therapeutic counterpart, yttrium-90 and lutetium-177 are used.
Besides these two main applications of gallium-68, a variety of studies work on 
the extension of the application scope.
For imaging of insulinoma pancreatic islets, several versions of 
68Ga-radiopharmaceuticals based on Exendin-4, a glucagon-like protein-1 receptor 
agonist, exist and it was demonstrated that [68Ga]Ga-DOTA-exendin-4 localizes 
insulinoma significantly better than 111In-radiolabelled radiopharmaceuticals [16].
Integrin αvβ3 and gastrin-releasing peptide receptor (GRPR) are usually 
overexpressed in human breast cancer, prostate cancer, breast cancer, colorectal 
cancer, pancreatic cancer, glioma, lung cancer, ovarian cancers, endometrial 
Figure 2. 
PET-images (A; C) and SPECT-images (B) of a patient with metastatic castrate-resistant prostate cancer 
(mCRPC) undergoing therapy with [177Lu]Lu-PSMA-617 with pre- and posttherapeutic 68Ga-PET-imaging 
using the diagnostic counterpart [68Ga]Ga-PSMA-11.
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cancers, renal cell cancer and gastrointestinal stromal tumors. An amphibian 
homolog of the mammalian gastrin-releasing peptide bombesin was intensively 
investigated, also radiolabelled with gallium-68, for imaging of GRPR. For integrin 
αvβ3, specific imaging probes usually use the peptide arginine-glycine-aspartic acid 
(RGD). For imagine of GRPR, several radiopharmaceuticals based on gallium-68 
were proposed, in particular [68Ga]Ga-BBN-RGD for breast cancer imagine [17], 
[68Ga]Ga-NOTA-Aca-BBN for glioma imagine [18], [68Ga]-NOTA-DUPA-RM26 for 
prostate cancer imagine .
Another promising area of application of 68Ga-based radiopharmaceuticals is 
the labeling of human epidermal growth factor receptor family (HER2) [19] and 
carcinoembryonic antigen (CEA) [20].
Even though gallium-68 is a very convenient radionuclide for use in radiophar-
macy, it is widespread in radiopharmaceuticals in comparison with other diagnostic 
isotopes. But usability and the commercially availability of generator simplified 
research and motivated developments with a view to a broad routine application.
4. Radiometals: special needs?
Radiolabeling with radiometals is in some ways challenging. Due to the very 
low amount of substance, other metals present in the reaction mixture can be 
serious problem and noticeably effect the radiolabeling. These metallic impurities 
can compete with gallium-68 for the chelating function of the precursor and are 
compared with gallium-68 (1 GBq equals to 9.73×10−12 mol) even when present at 
low levels (<ppm) clearly in excess number. They are result of external influences 
(e.g. production of starting materials) or are an intrinsic generator property (e.g. 
matrix; decay product). To avoid additional or larger impurities than necessary, the 
following is recommended by the IAEA [21]:
• Use plastic disposables/contact materials
• Avoid contact with metals of your working equipment during preparation of 
reagents (e.g. pipettes, spatulas, vials, etc.)
• Protect your working materials from direct contact with metals (e.g. surfaces, 
etc.)
• Use chemicals and water with lowest metal content as possible (e.g. ultra-pure 
grade)
• Do not use standard laboratory glassware (e.g. beakers, etc.)
• Consider coating of your fume hood.
5. Gallium-68: a brief profile
Gallium is located in group 13 in the 4th period. It has 31 known isotopes and 11 
metastable isomers including the two natural occurring stable isotopes gallium-69 
(60.11%) and gallium-71 (39.89%). Two gallium isotopes are applied in nuclear 
medicine for PET-imaging: gallium-67, which has the longest half-life (T1/2 = 3.26 d) 
of the instable 68Ga-isotopes, and gallium-68 (T1/2 = 67.71 min).
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Ga(III) is a hard Lewis acid forming complexes coordinating four, five or six 
ligands. The most stable complexes are the last-mentioned with a octahedral coor-
dination sphere in which oxygen, nitrogen and sulfur donor atoms form coordina-
tion bonds with Ga(III). To ensure the complex formation thorough pH, control is 
required to ensure deprotonation of the electron donor and to protect Ga(III) from 
forming Ga(OH)3 precipitating at pH 3–7 [22].
Gallium-68 is a positron emitter that decays with a half-life of 67.71 min and 
89% positron branching to stable zinc-68. The transition is accompanied by low-
abundant photon emission (1077 keV, 3.22%) [23]. Table 1 shows the mean and 
maximum energies of the positrons emitted in comparison to fluorine-18.
6. Availability: sources of gallium-68
6.1 Traditional: 68Ge/68Ga-generator
One of the reasons of the emerging application of gallium-68 in nuclear medi-
cine is its cyclotron-independency and availability via radionuclide generator.  Since 
the application of gallium-68 was a long time limited to research, advancements in 
generator design facilitated research on new 68Ga-radiopharmaceuticals as well as 
clinical use of the known.
Physical basis for radionuclide generators is the existence of the radioactive 
equilibria. The differentiation between radionuclide generations is based on the 
half-lives of the parent (1) and its daughter (2). Depending on the ratio between the 
two half-lives, three principal cases can be distinguished:
1. Transient equilibrium. Longer living parent but not more than factor 100:  
T1/2, 2 < T1/2,1 < 100.
2. Secular equilibrium. Much longer living parent: T1/2, 2 < < T1/2,1.
3. No equilibrium. Shorter living parent.
The basis for the 68Ge/68Ga-generator is the secular equilibrium between the 
parent radionuclide germanium-68 and its daughter gallium-68. Germanium-68 
decays with T1/2 = 270.95 days via electron capture to gallium-68. This transition is 
subsequently followed by decay of gallium-68 to stable zinc-68. At equilibrium, the 
quantity of gallium-68 produced is equal to the quantity of gallium-68 decaying, 
while the parent activity does not significantly decrease over many half-lives of 
the daughter. The theoretical maximum activity or equilibrium state for a certain 
generator system can be obtained at the time t (Figure 3):
  t  =  1 _ 
 λ 2 −  λ 1 
ln  λ 2  _
 λ 1 
(1)
Positron emitter Half-life  
~
 E β Eβ, max
[MeV]
Gallium-68 67.71 min 0.829 1.899
Flourine-18 109.77 min 0.250 0.634
Table 1. 
Comparison of mean ( ~ E β) and maximum (Eβ, max) positron energies of gallium-68 and fluorine-18 [24].
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For the 68Ge/68Ga system, equilibrium is reached after 14.1 h, representing maxi-
mum obtainable activity. Even if idle times of 12.5 half-lives are necessary to obtain 
maximum activities, the generators can be used more frequently. Within two half-
lives of gallium-68 already 75% of the maximum value is build-up and could be used.
The 68Ge/68Ga-generator system introduced in the 1960s by Gleason [10] 
underwent a lot of changes until today. From the first gallium cow providing 
gallium-68 after liquid–liquid extraction [10], nowadays the generators, based on 
a solid matrix (inorganic or organic) providing “ionic” 68Ga3+ eluates. The first 
commercially available generator of this type was developed by Cyclotron Ltd., 
Obninsk, Russian Federation [25] eluting gallium-68 with 0.1 M HCl with initial 
elution yields of ~80% and 68Ge breakthrough of 0.001% [26]. Since the introduc-
tion of this generator in 1996 [26], a lot has happened on the market. Today several 
manufacturers produce 68Ge/68Ga-generators, including ones with GMP grade (e.g. 
Isotopen Technologien Garching (ITG)) or with approval (e.g. GalliPharm® Eckert 
& Ziegler in the EU with marketing authorization, in the USA with type II drug 
master file (DMF) on file with FDA).
Even though these generators represent considerable improvements in 
68Ga-production, there are still some obstacles to direct radiolabeling with 
gallium-68. Beside the low radioactive and high [H+] concentration and 68Ge 
breakthrough, especially the presence of other trivalent metal ions is an inconve-
nience. As 1 GBq gallium-68 is equal to 9.73 pmol (9.73×10−12 mol), these metallic 
impurities, even present at low levels (<ppm), can be a serious problem as they can 
compete with gallium-68 for the chelating function of the precursor. In addition to 
the IAEA recommendations on externally introduced metallic contaminations [21], 
several procedures are available to reduce those metallic impurities, either intrin-
sic or externally introduced. These post-elution purification methods, so called 
post-processing’s, aim to improve the radioactive and [H+] concentration and the 
radionuclidic as well as chemical purity of the 68Ga-eluate. Beside fractionation of 
the eluate [11], anion-exchange (AEX) [13], cation-exchange (CEX) [27–29] and a 
combination thereof [30, 31] found to be suitable but only for fractionation but also 
are commercially used for cation-exchange.
6.2 Work in progress: cyclotron
Although 68Ge/68Ga-generators represent a convenient possibility for persistent 
patient care with 68Ga-radiopharmaceuticals, their 68Ga-activity available for 
Figure 3. 
Build-up kinetics of gallium-68 on the generator column after initial elution.
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radiolabeling underlies several restrictions resulting from generator design and 
physics. In conjunction with the sharp increase in demand in recent years, alterna-
tive production routes, preferably realizable with existing medical cyclotrons, 
moved into the focus.
Small to medium energy medical cyclotrons are suitable for 68Ga-production via 
the 68Zn(p,n)68Ga reaction using either a solid or a liquid target. Among the pos-
sible nuclear reactions [32, 33], it is the most reasonable leading to large production 
yields. For optimal results, the starting material zinc-68 as well as the proton energy 
needs to be selected with care to reduce co-production of long-living radioisotopes 
of gallium. Nevertheless, co-production of gallium-66 and gallium-67 is unavoid-
able due to the starting material and the excitation function of the 68Zn(p,2n)67Ga 
reaction [32, 33]. This has to be taken into account when producing gallium-68 
via cyclotron for radiopharmaceutical application as both radioisotopes cannot be 
separated from the desired gallium-68.
For production of gallium-68 via cyclotron, either a solid or a liquid target 
can be used. For both target types, a lot of options exist leading to a several 
considerations to be made. Solid targets, for example, can be pressed, electro-
plated, foil or fused, all types having their advantages and disadvantages which 
are not mentioned here. In a first instance, the choice of target will mostly be 
done due to the actual conditions of the site. An existing production site for 
18F-compounds which want to implement gallium-68 would probably choose the 
liquid target route, as the preconditions for a solid target (target holder, cool-
ing, target transfer and target processing) are expensive and likely not avail-
able. Compared with that, the liquid target is a quick and inexpensive option 
to obtain gallium-68 when a generator is not reasonable. A detailed overview 
about all possible alternatives and their advantages/disadvantages is given by 
the IAEA [21].
After irradiation, the gallium-68 needs to be purified from target material either 
if a solid or liquid target was used. The quantity of zinc necessary for the target 
need to be removed as it and all other metal impurities may perturb the radiolabel-
ing reaction of gallium-68. Intense research on this topic lead to several purification 
methods based on solvent extraction [34, 35], precipitation [36] and solid phase 
separation [37–44] and suitable for automation.
Solid-phase extraction using a cation exchange resin or hydroxamate resin is 
most appropriate for an effective separation of gallium-68 from unwanted met-
als and can be easily combined with a second resin. This second purification step 
allows an additional reduction of [H+] concentration to facilitate further processing 
of the final product [21]:
• Local conditions (expertise and equipment)
• Separation time (should be as short as possible)
• Acids (concentration and volume)
• Availability of materials
• Robustness of technique
• Ease of automation
• Possibility to recycle zinc-68 from target solution
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7. Radiolabeling: complexation chemistry in clinical settings
7.1 Manual
The manual radiolabeling approach is a leftover from times, where gallium-68 
was mainly used for research purpose, with lower 68Ga-activities and not in a clini-
cal setting for patient care. It is widely used in research and development of new 
tracers [11–13, 29, 30, 45–51]. Its main advantage is full control over the complete 
process (pH, time and temperature) and the possibility to easily access radiolabel-
ing kinetics.
Due to its general setup, this method is not suitable and indented for clinical use. 
Nevertheless, before the introduction of module systems or the cold kits, it was a 
long time, the only available method.
In general (Figure 4), the first step is the preparation of the reaction mixture 
by mixing [68Ga]GaCl3 with a suitable buffer in the required pH range and the 
radiolabeling precursor. Here, the purified cyclotron-produced, generator eluate or 
post-processed gallium-68 can be used.
Then, the reaction vial is incubated to form the 68Ga-complex. Reaction period 
and reaction temperature are selected in accordance to the kinetics of the complex 
formation of gallium with the used chelator.
After the reaction, the reaction mixture can be purified using, for example, solid 
phase extraction from, for example, free gallium-68 and residual germanium-68 
impurities.
In the final step, the 68Ga-radiopharmaceutical is sterile filtrated and formulated 
in the product vial (Table 2).
7.2 Module
With the growing interest for gallium-68 not only for research but also for 
clinical routine and patient care the need for pharmacopeia compliant prepara-
tion of 68Ga-radiopharmaceuticals. This led to promotion of the automation of the 
traditional manual synthesis from which numerous semi- and fully automated 
devices have emerged. Today, those systems are designed with respect to Good 
Figure 4. 
Schematic description of the 68Ga-radiolabeling procedure (I) preparation of the reaction mixture by 
adding gallium-68 eluted from a generator or after post-processing to a mixture of a suitable buffer and 
precursor, (II) incubation of the reaction mixture for a certain time. If elevated temperatures are needed 
or not depends on the chelator, (III) purification step using solid phase extraction (SPE). For example, the 
68Ga-radiopharmaceutical is trapped on a SPE C18-cartridge where it is washed with water to remove free 
gallium-68, germanium-68 and buffer, (IV) the purified product is finally eluted with diluted ethanol solution 
and formulated after sterile filtration in the product vial.
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Manufacturing Practice (GMP) Guidelines provided, for example, by the FDA, 
EU/EMA, ICH, WHO or others [55]. They use software and methods designed to 
minimize user interventions and utilize single-use consumables produced under 
GMP standard.
While the module production requires a fully equipped laboratory and quality 
control, it reduces radiation exposure of the operator the production process in 
terms of higher reliability and reduced variability [56–58].
Accordingly, the amount of contaminated waste materials is higher due to 
the procedure as well the complete quality control. Nevertheless, these systems 
are suitable for a variety of tracers and in most cases for more radionuclides not 
only for gallium-68 (e.g. Scintomics GRP series; Eckert & Ziegler Modular-Lab 
PharmTracer; Trasis AllInOne).
7.3 Kits
Recently, cold kits for radiolabeling entered the scene enable production of 
68Ga-radiopharmaceuticals as easy as that of 99mTc-radiopharmaceuticals. This 
method allows the reconstitution of the pre-formulated cold kit with no previous 
post-processing of the eluate or subsequent purification of the final product. They 
are available in GMP quality and leaves only minimum quality control tests to the 
final user responsibility to verify the reconstitution procedure.
For example, the European Pharmacopeia (Ph. Eur.) states the marketing 
authorization (MA) holder of a licensed kit is responsible to ensure compliance of 
the kit with the requirements of its MA, while the final user carries the responsibil-
ity for the quality of the preparation and the handling. If the given instructions are 
not strictly followed or if one or more components used for the reconstitution do 
not have MA, it is the responsibility of the final user to demonstrate that the quality 
of the final preparation is suitable for the intended, use [26].
Therefore, preparation as well as quality control requires at least the equip-
ment according to the instructions provided by the manufacturer. In addition, 
minimum contaminated waste materials remain. It has to be noted, according to 
the Ph. Eur. that applies only for licensed kits in combination with the generator 
mentioned in the instructions from the manufacturer. In contrast, unlicensed 
kits or a licensed kit used with an unlicensed generator or cyclotron produced 
gallium-68 also require full quality control according to the monograph. 
Additionally, local authorities may require more detailed quality control even for 
licensed kits.
Indeed, these cold kits contain relatively high amounts of precursor and 
additional filler materials. They still require manual handling and are only 
commercially available as single-dose kits for radiolabeling PSMA-11 (e.g. illu-
met™) and DOTA-TOC (e.g. NETSPOT®). In addition, the use of unpurified 
generator eluates requires very strict specifications for the generators in terms of 
68Ge-breakthrough to ensure the quality of the final product. Nevertheless, there 
is a possibility for small sites to offer 68Ga-radiopharmaceuticals to their patients 
without great expense.
Chelator Radiolabeling conditions
DOTA 37–90°C, 10–30 min, pH 4.0–5.5 [52, 53]
HBED 25°C, 10–20 min, pH 4.0–4.5 [54]
Table 2. 
Radiolabeling conditions for gallium-68 for DOTA and HBED.
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8. Quality control: pharmaceutical needs and radioactive specialties
Quality defects of pharmaceutical can lead to serious consequences when they 
are applied. Consequently, the regulatory framework for production and quality 
control is very strict. In general, one main requirement in the production of phar-
maceuticals is a comprehensive, integrated system of quality assurance. Its purpose 
is the monitoring and documentation of all processes as well as their functionality 
with respect to the rules of GMP.
Because radiopharmaceuticals are pharmaceutical preparations containing 
minimum one radionuclide for diagnostic or therapeutic purpose, in principle the 
same rules apply. Their quality control is intended to ensure that the quality meets 
the predefined specifications for the radiopharmaceutical. These specifications take 
into account the radionuclide, the precursor, the preparation process, the formula-
tion and the intended administration route. Due to the nature of the contained 
radionuclides, not all necessary quality control tests can be performed before release 
for administration and require retrospective examination. In the available mono-
graphs, it is indicated if a test need not to be completed before release of the batch.
In the case of gallium-68, the short half-live and the limited available activities 
lead to further challenges. Here are sophisticated logistics for preparation and qual-
ity control essential.
In general, quality control of 68Ga-radiopharmaceuticals should include the 
following tests and information [59–61]:
1. Characters/appearance. Should discover any visible container defects. The qual-
ity of the final product in terms of absence of particular matter [62] and/or 
turbidity should be ensured as well as its correct appearance. Typically per-
formed by visual inspection.
2. pH determination. Should ensure that the pH of the final product is in the 
necessary range for its purpose. For the final injectable formulation of a radio-
pharmaceutical, the pH should be closed to the physiologic value of 7.4. With 
regard to the relatively low volume of radiopharmaceuticals and depending on 
the injected volume and rate, a wider range (3.5–8.5) is applicable. Contrary to 
this, the pH of the radionuclide precursor gallium-68 should not exceed 2 to 
prevent the formation of unwanted 68Ga-colloids.
3. Radionuclidic identification. Identification of a radionuclide is generally con-
ducted by determination of its half-life and/the nature and energy of its 
radiation emitted. For positron emitters like gallium-68 instead of energy and 
nature of the radiation, the identification is based on a γ-spectrum additional 
to their half-life determination (e.g. with dose calibrator).
4. Radiochemical identification. Identification of the desired radiochemical species 
via HPLC and/or TLC exploiting different chemical behavior of the different 
radiochemical species.
5. Radionuclidic purity. Due to the contribution or formation of other radionu-
clides during the production of gallium-68, their amount present in the final 
radiopharmaceutical must be determined. Depending on the production route 
of gallium-68, different limits for radionuclidic impurities may apply. The test 
for those long-living radionuclides need to be performed after complete decay 
of the sample using γ-spectrometry, representing a test performed after release 
of the batch.
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6. Radiochemical purity. Should discover all chemical forms containing the radio-
nuclide and determine their percentage of the total radioactivity of the prod-
uct. These radiochemical impurities arise from the synthesis method, radiolysis 
or the radionuclide production and can lower the quality of the final diagnostic 
examination. Principally be determined by any suitable analytical method but 
with respect to the short half-life and radiation TLC and HPLC are normally 
used for quality control of 68Ga-radiopharmaceuticals.
7. Chemical purity. The chemical purity refers to the amount of the specified 
chemical form of a preparation if radioactivity is present or not [61]. Purity 
assessment is of special importance when diagnostic or therapeutic properties 
are directly linked to chemistry [63]. Therefore, particular attention is neces-
sary for pharmacologically active impurities as they can affect the diagnostic 
value of the examination. The chemical purity of 68Ga-radiopharmaceuticals is 
normally ascertained with TLC and/or HPLC.
8. Residual solvents. Ph. Eur. as well as US pharmacopeia defines residual solvents 
as organic volatile chemicals used in the manufacture of drug substances/ac-
tive substances, excipients or in the preparation of medicinal products (Eur. 
Ph. 5.4.; USP 467). As they represent a risk of health, they should be deter-
mined. Determination can be performed using gas chromatography (GC)
It has to be noted that the texts about residual solvents not cover solvents added 
by purpose or solvates. For those other limits and regulations may apply.
9. Microbiological contamination. Parenteral administered radiopharmaceuticals 
need to be compliant in terms of bacterial endotoxins or pyrogens as well as 
sterility
Bacterial endotoxins are known to cause a wide spectrum of nonspecific patho-
physiological reactions (fever, changes in white blood cell counts, hypotension, 
disseminated intravascular coagulation, shock and death) leading to death when 
injected in most mammals [64]. Thanks to the development of more and more 
efficient systems today tests (LAL-test) for bacterial endotoxins (BET) can be 
completed before release of the batch of the 68Ga-radiopharmaceuticals.
In contrary, the test for sterility of 68Ga-radiopharmaceuticals via direct inocula-
tion is necessarily retrospective nevertheless indispensable. Additionally, to the 
direct inoculation test the integrity of the sterile filter used for sterile filtration of 
the final product is performed. Due to the need for sterilization to obtain a sterile 
parenteral solution and the not applicability of autoclaving for short-living radio-
pharmaceuticals membrane filtration is normally the method of choice. The tests 
for the filter integrity (e.g. bubble point, diffusion rate, pressure hold) have the 
advantage that they can be completed before batch release.
10. Radioactivity content/concentration. Defines the activity, measured with a dose 
calibrator, within the volume of the final preparation.
11. Specific radioactivity. The specific radioactivity (activity of the radionuclide 
per unit mass either of the element or the desired chemical form) is calculated 
using the concentrations of radioactivity and the chemical form. Referring to 
the consensus nomenclature rules for radiopharmaceutical chemistry [65], 
the specific activity is expressed as measured activity per gram of compound 
(e.g. MBq/μg), while it is called molar activity when expressing the measured 
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activity per mole of compound (MBq/nmol) [65]. As gallium-68 requires a 
complex ligand which is normally not fully removed during the final product 
purification, the measured specific or molar activity is lower than actual. Then 
the correct terms are apparent specific or molar activity [65].
The specific or molar activity is always given with reference date and time.
8.1 Generator obtained gallium-68
For gallium-68 obtained from a 68Ge/68Ga-generator, the Ph. Eur. contains a 
distinct monograph (#2464). This monograph specifies the quality characteristics 
of 68Ga chloride solutions for radiolabeling independently if obtained directly from 
a generator or after post-processing the generator eluate. If a further purification of 
the generator eluate is performed, this has to be stated on the label.
Use of generator-produced gallium-68 in the USA is regulated under 10 CFR 35. 
1000 and 10 CFR 30.33 [66] (Table 3).
For incoming starting materials, the GMP guidelines prescribe certain handling 
procedures to ensure their quality and suitability. For material acceptance of an 
incoming new 68Ge/68Ga-generator, minimum controls are needed. This include the 
conformation of the radionuclide identity, 68Ge-breakthrough and of activity stated 
in the Certificate of Analysis (CoA) all verified by activity measurement if possible 
[60]. Establishment of additional acceptance criteria may be required.
Nevertheless, the 68Ga-eluate used for radiolabeling should meet those 
specifications (Table 4), their verification is in clinical routine not possible 
for every production. This results from the different production routes of 
68Ga-radiopharmaceuticals, which do not intend or allow an intervention for 
sampling of the eluate. Thus, the quality control of the starting material gallium-68 
or of the final radiopharmaceuticals is allowed. This should include at least tests for 
68Ge-breakthrough, radionuclidic purity, radiochemical purity and chemical purity.
8.2 Cyclotron produced gallium-68
When produced via accelerator, the presence of the radioisotopes gallium-66 
and gallium-67 is difficult to avoid due to zinc-66 and zinc-67 contaminating the 
WHAT? HOW? LIMITS
Appearance Visual inspection Clear, colorless solution
pH pH indicator strips <2
Radionuclide identity Half-life determination 62–74 min
γ-spectrometry 511, (1022), 1077, (18,839 keV
Radionuclidic purity γ-spectrometry <0.1% long living impurities
<0.001% germanium-68
Radiochemical purity TLC >95% 68Ga(III)
Chemical purity ICP-AES/ICP-MS <10 μg/GBq Fe
<10 μg/GBq Zn
Bacterial Endotoxins LAL test ≤175 EU/total volume
Table 3. 
Quality control specifications for diluted hydrochloric solutions of generator produced gallium-68 as defined by 
the Ph. Eur. (monograph #2464) [59].
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target material. In return, germanium-68 is absent. Therefore, quality control and 
specifications for radionuclidic impurities are different to generator-produced 
gallium-68.
For gallium-68 obtained from a cyclotron, a new monograph (#3109) is already 
submitted for adoption to the Ph. Eur. [67]. This monograph specifies the quality 
characteristics of 68Ga-chloride solutions for radiolabeling obtained by irradiation 
of enriched zinc-68 in an accelerator with subsequent isolation of gallium-68 in 
acidic solution (Table 5).
Similar to generator-produced gallium-68, quality control can be performed of 
the starting material obtained via cyclotron or on the final radiopharmaceutical. If 
quality control of the final radiopharmaceuticals performed, it should include at 
least tests for 68Ge-breakthrough, radionuclidic purity, radiochemical purity and 
chemical purity.
8.3 68Ga-Radiopharmaceuticals
As an example for the specifications and limitations for a 68Ga- 
radiopharmaceutical quality control as requested by the monograph #2464 of the 
Manufacturer Type Maximum nominal activity
Eckert & Ziegler (Germany) GalliaPharm® 2.4 GBq
IGG100 2.4 GBq
Obninsk Cyclotron Ltd. (Russia) 3.7 GBq
IRE Elit (Belgium) Galio Eo® 1.85 GBq
Galli Ad® 1.85 GBq
ITG (Germany) 2 GBq
iThemba Labs (South Africa) 1.85 GBq
Pars Isotopes (Iran) Pars-GalluGEN 2.59 GBq
Table 4. 
In all conscience a list of 68Ge/68Ga-generators available.
WHAT? HOW? LIMITS
Appearance Visual inspection Clear, colorless solution
pH pH indicator strips <2
Radionuclide identity Half-life determination 62–74 min
γ-spectrometry 511, (1022), 1077, (18,839 keV
Radionuclidic purity γ-spectrometry <0.1% long living impurities
<2% gallium-66 & gallium-67
Radiochemical purity TLC >95% 68Ga(III)
Chemical purity ICP-AES/ICP-MS <10 μg/GBq Fe
<10 μg/GBq Zn
Bacterial Endotoxins LAL test ≤175 EU/total volume
Table 5. 
Quality control specifications for diluted hydrochloric solutions of accelerator-produced gallium-68 as defined 
by a draft of a monograph for the Ph. Eur. Submitted for adoption (#3109) [67].
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Ph. Eur. [68Ga]Ga-DOTA-TOC is provided [59]. It has to be noted, that monograph 
#2464 is currently under revision which can lead to different limits in feature 
(Table 6).
9. Regulatory aspects: the most important at the end
The quality control for a certain 68Ga-radiopharmaceutical depends on the 
production route of gallium-68, the synthesis route of the radiopharmaceutical as 
well as of the relevant legislation.
As descripted in Section 7.2, the respective production route leads to different 
radionuclidic impurities (germanium-68 vs. gallium-66 & gallium-67) that need 
to take into account for the final product specifications. However, this is not yet 
implemented in the pharmacopeias but is in part already in progress. For example, 
the monograph for [68Ga]Ga-DOTA-TOC (#2464) of the Ph. Eur. is currently in 
revision to take into account the cyclotron production of gallium-68 [68].
In general, the quality of the final radiopharmaceutical needs to fulfill all specifi-
cations given by the relevant legislation or pharmacopeia independent from the syn-
thesis route. Nevertheless, it may be possible to dispense individual tests given, for 
example, for licensed kit preparations. For example, the Ph. Eur. states in its general 
notices “An article is not of Pharmacopoeia quality unless it complies with all the 
requirements stated in the monograph. This does not imply that performance of all 
the tests in a monograph is necessarily a prerequisite for a manufacturer in assessing 
compliance with the Pharmacopoeia before release of a product. The manufacturer 
may obtain assurance that a product is of Pharmacopoeia quality on the basis of 
its design, together with its control strategy and data derived, for example, from 
WHAT? HOW? LIMITS
Appearance Visual inspection Clear, colorless solution
pH pH indicator strips < 2
Radionuclide identity Half-life determination 62 to 74 min
γ-spectrometry 511, (1022), 1077, (18,839 keV
Radionuclidic purity γ-spectrometry <0.1% long living impurities
<0.001% germanium-68
Radiochemical purity TLC >91%
TLC <3% [68Ga]Ga in colloidal form
HPLC <2% [68Ga]Ga3+
Chemical purity ICP-AES/ICP-MS <10 μg/GBq Fe
<10 μg/GBq Zn
HPLC <50 μg/V DOTA-TOC and metal complexes of 
DOTA-TOC
TLC <200 μg/V HEPES
GC <10% V/V and <2.5 g per administration
Bacterial endotoxins LAL test ≤175 EU/total volume
Sterility Direct inoculation sterile
Table 6. 
Quality control specifications [68Ga]Ga-DOTA-TOC as given by the Ph. Eur. For generator-produced 
gallium-68 (monograph #2464) [59].
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validation studies of the manufacturing process” [59]. Further details can be found 
in the general chapter on extemporaneous preparation of radiopharmaceuticals 
(5.19) and the general monograph radiopharmaceutical preparations (#0125) [59].
Nevertheless, the competent authorities may request further quality control test-
ing. Therefore, it is strongly recommended, especially in case of doubt, to consult 
the competent authorities.
The implementation of a new radiopharmaceutical into the certain 
pharmacopeias is a protracted process. Therefore, several commonly used 
68Ga-radiopharmaceuticals are not yet represented with own monographs in the 
pharmacopeias (e.g. [68Ga]Ga-PSMA-11). Nevertheless, such radiopharmaceuticals 
can be produced with consideration of the general notices, texts, monographs and 
along the lines of, for example, the monograph for [68Ga]Ga-DOTA-TOC. Again, in 
case of doubt, the competent authorities should be consulted.
10. Conclusion
Gallium-68 is a well-researched radionuclide with growing importance for clini-
cal practice triggered by the development of new tracers expanding its application 
and the increasing demand for theranostic patient care.
Its availability via radionuclide generator in combination with comparably easy 
coordination chemistry enables a patient care even in places where the cyclotron-
produced PET-radionuclides are unavailable and, in the case of NETs, enables 
patient care where no 18F-alternative exists.
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AEX anion-exchange
API active pharmaceutical ingredient
BET bacterial endotoxin test
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DMF drug master file
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